Compare Amphastar Pharmaceuticals Inc (AMPH) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Incyte Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Incyte Corporation trades at $116.8 (market cap $23.32B). The key difference: Incyte Corporation is far larger — about 28.2× Amphastar Pharmaceuticals Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | INCY | |
|---|---|---|
Market Cap | $826.08M | $23.32B |
Sector | Health | Health |
52-Week High | $30.81 | $118.52 |
52-Week Low | $16.87 | $67.38 |
Enterprise Value | $1.22B | $19.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
INCY trades at $116.71, down 1.53% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported robust revenue of $5.14 billion in 2025, with a net income margin of 26.71%, and recent news highlights regulatory approvals and portfolio expansion, including the acquisition of Vega Therapeutics.
The outlook is positive, driven by earnings beats, product pipeline advancements, and analyst consensus leaning buy. Key risks include execution of recent acquisitions and reliance on key products like Opzelura, but institutional sentiment remains strong with a consensus price target of $107.88.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
